Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.06+0.02 (+1.92%)
Close on Nov 17, 2026Market cap $106.36MP/E –Yield –
Earnings
Cellectis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2026
$5.23M
-68.7% on a year earlier
Basic and diluted adjusted net loss per share attributable to shareholders of Cellectis ($/share), Q2 FY2026
-$0.19
-$0.22 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Cellectis's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | $5.23M | -68.7% | -$0.22 | -$0.19 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 20, 2026during market hours | $10.40M | – | -$0.26 | -$0.24 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025during market hours | $16.73M | – | -$0.24 | -$0.22 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023during market hours | – | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023during market hours | $178.00K | – | -$0.19 | -$0.15 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 6, 2023during market hours | – | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | – | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022during market hours | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Cellectis has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Cellectis puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Cellectis filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?